Table 3.

Summary relative risk (SRR) of site-specific cancers following NMSC, BCC, and SCC among registry-based studies

Site of second primary cancerNMSC SRR (95% CI)*NMSC: males SRR (95% CI)*NMSC: females SRR (95% CI)*BCC SRR (95% CI)*SCC SRR (95% CI)*
Lung1.23 (1.13-1.33)1.27 (1.16-1.39)1.19 (1.06-1.33)1.13 (1.01-1.27)1.34 (1.22-1.47)
Breast1.04 (0.96-1.14)1.04 (0.96-1.14)1.08 (0.99-1.19)0.97 (0.88-1.08)
Colorectal1.05 (0.97-1.13)1.05 (0.95-1.16)1.03 (0.94-1.13)1.02 (0.93-1.13)1.03 (0.93-1.15)
Melanoma2.74 (2.49-3.02)2.73 (2.52-2.96)2.61 (2.24-3.05)2.75 (2.39-3.16)2.84 (2.45-3.29)
Pancreas0.94 (0.82-1.07)1.07 (0.97-1.18)0.91 (0.78-1.06)
Leukemia1.26 (1.04-1.52)1.45 (1.17-1.79)1.24 (0.99-1.55)1.12 (0.93-1.35)1.45 (0.93-2.11)
Cervix0.93 (0.62-1.41)0.93 (0.62-1.41)0.84 (0.50-1.41)
Non–Hodgkin lymphoma1.58 (1.37-1.81)1.56 (1.33-1.84)1.58 (1.37-1.82)1.39 (1.22-1.58)2.00 (1.80-2.22)
Myeloma1.18 (1.06-1.32)
Salivary gland4.57 (2.92-7.15)5.22 (3.32-8.22)3.65 (1.91-6.95)7.15 (4.09-12.52)
Thyroid1.28 (0.95-1.71)1.72 (0.55-5.33)1.23 (0.99-1.53)1.24 (0.92-1.67)
Prostate1.04 (0.98-1.12)1.04 (0.98-1.12)1.07 (0.97-1.17)1.00 (0.94-1.07)
Lip2.38 (2.03-2.79)2.09 (1.88-2.31)4.45 (2.76-7.19)3.79 (3.15-4.57)
Mouth and pharynx1.69 (1.31-2.18)1.94 (1.50-2.49)1.87 (1.26-2.78)1.32 (1.13-1.55)2.05 (1.33-3.19)
Esophagus1.06 (0.85-1.32)1.15 (0.92-1.45)1.11 (0.90-1.36)0.90 (0.67-1.21)1.21 (0.83-1.74)
  • *95% confidence interval.

  • Not applicable.

  • RR estimate presented in fewer than 5 studies.